Glial Fibrillary Acid Protein Test

Your brain could be under stress right now, and no standard blood test would tell you. GFAP (glial fibrillary acidic protein) is one of the few blood markers that gives you a direct window into what is happening inside your brain. When the star-shaped support cells in your brain, called astrocytes, are injured or activated by disease, they release this protein into your bloodstream, where it can be measured with a simple blood draw.

What makes GFAP valuable is its specificity to the brain. Unlike many blood tests that reflect whole-body processes, GFAP comes almost exclusively from astrocytes in your central nervous system. A rising level signals that something is activating or damaging these cells, whether that is a head injury, early Alzheimer's disease, a stroke, or chronic neuroinflammation you cannot feel yet.

What Astrocytes Do and Why Their Distress Matters

Astrocytes are the most abundant support cells in your brain and spinal cord. They maintain the blood-brain barrier (the protective wall that controls what enters your brain from your bloodstream), regulate the chemical environment around your neurons, and help deliver nutrients. GFAP is the internal scaffolding that gives these cells their shape and structural integrity.

When astrocytes sense damage, infection, or disease nearby, they shift into a reactive state. Scientists call this process reactive astrogliosis. Think of it as a cellular alarm response: the astrocytes swell, change shape, and ramp up GFAP production. Some of this protein escapes through the blood-brain barrier and into your circulation. The more GFAP in your blood, the more astrocyte activation is happening in your brain.

Alzheimer's Disease Risk

The most exciting preventive application of GFAP testing is its ability to detect Alzheimer's-related brain changes years before memory problems appear. In a UK Biobank study of over 48,000 participants followed for an average of 13 years, elevated GFAP levels predicted new dementia diagnoses up to 15 years in advance. People with the highest levels were roughly 2 to 3 times more likely to develop dementia compared to those with the lowest levels, even after adjusting for age, sex, and other risk factors.

In people with genetic forms of Alzheimer's disease (mutations that guarantee eventual onset), plasma GFAP rises approximately 10 years before expected symptom onset. This makes it one of the earliest detectable blood changes in the Alzheimer's process, appearing after amyloid plaques begin forming but before significant brain shrinkage or cognitive decline begins.

Among cognitively normal older adults in the A4 Study (949 participants), higher baseline GFAP predicted faster cognitive decline, greater risk of progressing to mild cognitive impairment, and accelerated brain shrinkage in Alzheimer's-vulnerable regions. The effect was stronger in women. In a separate Swedish community study of over 2,100 dementia-free older adults followed for up to 16 years, GFAP predicted dementia with negative predictive values exceeding 90%, meaning a low result was highly reassuring.

Traumatic Brain Injury

GFAP's first FDA-cleared use is in evaluating mild traumatic brain injury (concussion). When someone hits their head, the standard next step is often a CT scan to check for bleeding. But most concussions do not cause bleeding visible on CT, and most CT scans after mild head injuries come back normal. A blood GFAP level below the clinical cutpoint (30 pg/mL on the FDA-cleared assay) can help rule out the need for a CT scan, with a negative predictive value above 99%.

GFAP also picks up brain injuries that CT misses entirely. In the TRACK-TBI study of over 2,500 patients, about 27% to 30% of people with normal CT scans still had abnormalities visible on MRI. Elevated GFAP identified many of these CT-invisible injuries. A meta-analysis of 22 studies (3,709 patients) found that for predicting death after traumatic brain injury, GFAP had a sensitivity of 86% and specificity of 66%.

Stroke

GFAP rises much faster and higher after a hemorrhagic stroke (bleeding in the brain) than after an ischemic stroke (a blocked blood vessel). This difference makes it useful for distinguishing between the two types in the first hours, when treatment decisions are time-sensitive. A 2025 study using a point-of-care device found that prehospital GFAP measurement could identify hemorrhagic strokes with positive predictive values of 90% to 96%, depending on the patient's age.

In a study of 286 patients with ischemic stroke admitted within 24 hours, those in the highest quarter of GFAP levels had roughly 6 times the risk of a poor outcome compared to those in the lowest quarter, even after adjusting for standard risk factors.

Cardiovascular Mortality

GFAP is not just a brain marker in terms of consequences. In the Chicago Health and Aging Project (1,327 older participants), higher GFAP was associated with a roughly 74% increased risk of cardiovascular death after adjusting for age, sex, education, body mass index, and chronic health conditions. This association likely reflects the interconnection between brain health and heart health: chronic vascular disease damages small blood vessels in the brain, activating astrocytes and releasing GFAP.

Multiple Sclerosis and Neuroinflammation

In multiple sclerosis (MS), GFAP tracks a specific and often underrecognized component of disease progression. While neurofilament light chain (NfL), another brain blood test, captures acute inflammatory flares and relapses, GFAP reflects the slower, smoldering process of chronic neurodegeneration and progressive disability that accumulates independent of relapses. A meta-analysis of 12 studies (1,731 participants) confirmed that GFAP levels in MS patients are significantly higher than in healthy controls.

GFAP is also elevated in neuromyelitis optica spectrum disorder, where it can help distinguish active disease attacks from remission periods. Cutoff levels between 90 and 337 pg/mL have been proposed for this purpose, though consensus thresholds are still being established.

Reference Ranges

GFAP levels rise with age in healthy people, so a number that would be concerning in a 40-year-old might be perfectly normal in a 75-year-old. Sex also matters: women tend to have higher levels than men, especially after age 50. Any interpretation of your result must account for both factors.

These ranges come from studies using the Simoa and MSD immunoassay platforms. Your lab may use a different assay, and results are not directly interchangeable across platforms despite strong correlations between them. Always compare your results within the same lab and assay over time. The FDA-cleared clinical cutpoint for traumatic brain injury evaluation is 30 pg/mL on the iSTAT point-of-care device, but this threshold was designed for acute injury assessment, not for preventive health screening.

No established "optimal" range exists for preventive health purposes. GFAP is a Tier 2 emerging clinical marker for most applications outside of acute brain injury: published reference ranges exist and outcome data are accumulating rapidly, but standardized preventive-screening cutpoints have not been established. Your own trend over time is more informative than any single number.

When Results Can Be Misleading

Kidney function is one of the most common confounders. Your kidneys help clear GFAP from your blood, so reduced kidney function (lower eGFR) can raise GFAP levels even when your brain is fine. One study found that measured kidney filtration rate was an independent predictor of GFAP concentration. If your kidney function is impaired, your GFAP result may overestimate brain-related problems.

Body mass index shows an unexpected inverse relationship: people with higher BMI tend to have lower GFAP levels. The reason is unclear, but this means GFAP may underestimate brain stress in people with obesity. Diabetes also appears to lower GFAP slightly through unknown mechanisms.

Time of day matters. GFAP concentrations rise between 9 AM and noon, following a semidiurnal pattern. If you are tracking your trend over time, try to draw your blood at the same time of day each visit. Corticosteroid medications (such as prednisone or dexamethasone) can suppress brain GFAP expression by 20% to 40% based on animal studies, potentially masking an underlying problem on your blood test. This effect occurs at the level of gene expression in astrocytes rather than by causing or treating brain disease, so it represents a measurement confounder rather than a true change in brain health.

Recent surgery can temporarily raise GFAP, with higher intraoperative increases linked to postoperative delirium. Any acute neurological event (stroke, seizure, head trauma) will spike GFAP for days to weeks. Wait at least several weeks after any such event before drawing GFAP for baseline or trend purposes.

Tracking Your Trend

A single GFAP reading is a snapshot. The real power of this test comes from tracking it over time. The within-person biological variation is only about 9.7%, meaning your level is relatively stable from day to day when nothing is changing in your brain. But a true change needs to exceed the reference change value of about 37% to confidently distinguish a real shift from normal biological noise.

Because GFAP rises years before Alzheimer's symptoms appear, getting a baseline in your 40s or 50s gives you a personal reference point. If your level rises meaningfully over subsequent years, that trajectory carries far more information than any single number compared to a population average. Retest annually, or every 6 months if you are actively making changes to reduce neurological risk (exercise, sleep optimization, cardiovascular risk reduction). Use the same lab and assay platform each time so your results are directly comparable.

Assay platforms can produce systematically different numbers even when measuring the same sample. Correlation between platforms is strong (r = 0.83 to 0.96), but the absolute values differ enough that switching labs mid-trend can create a false signal. Pick one lab and stay with it.